Getting closer to the truth: Overcoming research challenges when estimating the financial impact of worksite health promotion programs

American Journal of Health Promotion

Volumn 15, Issue 5, 2001, Pages 289-295

  Ozminkowski, Ronald J ^a   Goetzel, Ron Z ^a  

^a MEDSTAT GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HEALTH PROMOTION; HEALTH STATUS; RESEARCH; WORK ENVIRONMENT;

EID: 0035026042     PISSN: 08901171     EISSN: None     Source Type: Journal    
DOI: 10.4278/0890-1171-15.5.289     Document Type: Article

References (46)

1. Cook TD, Campbell DT. Quasi-Experimentation: Design and Analysis Issues for Field Settings. Boston, MA: Houghton Mifflin Company; 1979.
2. Pelletier KR. A review and analysis of the clinical and cost-effectiveness studies of comprehensive health promotion and disease management programs at the worksite: 1995-1998 update IV. Am J Health Promot. 1999; 13:333-345.
3. Aldana SG. Financial impact of worksite health promotion and methodological quality of the evidence. Art Health Promot. 1998;2:1-8.
4. Heaney CA, Goetzel RZ. A review of health-related outcomes of multicomponent worksite health promotion programs. Am J Health Promot. 1997;11:290-308.
5. Sciacca J, Seehafer R, Reed R, Mulvaney D. The impact of participation in health promotion on medical costs: a reconsideration of the Blue Cross Blue Shield of Indiana Study. Am J Health Promot. 1993;7:374-395.
6. Bertera R. Behavioral risk factor and illness day changes with workplace health promotion: two-year results. Am J Health Promot. 1993;7:365-373.
7. Edington DW, Yen LT, Witting P. The financial impact of changes in personal health practices. J Occup Environ Med. 1997;39:10.37-1047.
8. Goetzel RZ, Dunn RL, Ozminkowski RJ, Satin K, Whitehead D, Cahill K. Differences between descriptive and multivariate estimates of the impact of Chevron Corporation's Health Quest Program on medical expenditures. J Occup Environ Med. 1998;40:538-545.
9. Ozminkowski RJ, Dunn RL, Goetzel RZ, Cantor R, Murnane J, Harrison M. A return on investment evaluation of the Citibank, N.A. Health Management Program. Am J Health Promot. 1999;14:31-43.
10. Yen LT, Eddington DW, Witting P. Corporate medical claim cost distributions and factors associated with high-cost status. J Occup Med. 1994;36: 505-515.
11. Goetzel RZ, Anderson DR, Whitmer RW, Ozminkowski RJ, Dunn RL, Wasserman J. The relationship between modifiable health risks and health care expenditures. J Occup Environ Med. 1998;40:843-854.
12. Lynch WD, Golaszewski RJ, Clearie A, Vickery DM. Characteristics of self-selected responders to a health risk appraisal: generalizability of corporate health assessments. Am J Public Health. 1989;79:887-888.
13. Goetzel RZ, Juday T, Ozminkowski RJ. What's the ROI? A systematic review of return on investment studies of corporate health and productivity management initiatives. AWHP's Worksite Health. 1999;7:12-19.
14. Getzen TE. Medical care price indexes: theory, construction, and empirical analysis of the U.S. series 1927-1990. Adv Health Econ Health Serv Res. 1992;13:83-128.
15. Newhouse JP. Measuring medical prices and understanding their effects. J Health Adm Educ. 1989;7:19-26.
16. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care. 1993; 31:403-418.
17. Keeler EB, Cretin S. Discounting of life-saving and other non-monetary benefits. Manage Sci. 1983;29:300-310.
18. Viscusi WK. Discounting health effects for medical decisions. Chapter 7. In: Sloan F, ed. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. New York, NY: Cambridge University Press; 1995:125-148.
19. Gramlich EM. Benefit-Cost Analysis of Government Programs. Englewood Cliffs, NJ: Prentice-Hall Inc; 1981.
20. Nas T. Cost-Benefit Analysis: Theory and Application. Thousand Oaks, CA: Sage Publications; 1996.
21. Warner KE, Luce BR. Cost-Benefit and Cost-effectiveness Analysis in Health Care: Principles, Practice, and Potential. Ann Arbor, MI: Health Administration Press; 1982.
22. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
23. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs. 2nd ed. New York, NY: Oxford University Press; 1997.
24. Sloan FA, ed. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. New York, NY: Cambridge University Press; 1995.
25. Hargreaves WA, Shumway M, Hu T-W, Cuffel B. Cost-Outcome Methods for Mental Health. San Diego, CA: Academic Press; 1998.
26. Goetzel RZ, Ozminkowski RJ. How to Evaluate Workplace Health Promotion Programs. Keego Harbor, MI: American Journal of Health Promotion; 2000.
27. Substance Abuse and Mental Health Services Administration. Workplace Managed Care Financial Cost Research Evaluation Guide. Available at: http:// wmcare.samhsa.gov/fradocuments.html. Accessed February 9, 2001.
28. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. J Am Med Assoc. 1996; 276:1172-1180.
29. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. J Am Med Assoc. 1996;276:1339-1341.
30. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Assoc. 1996;276:1253-1258.
31. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? Chapter 5. In: Sloan F, ed. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceutical and Other Medical Technologies. New York, NY: Cambridge University Press; 1995: 77-98.
32. Duan N, Manning WG Jr, Morris CN, Newhouse JP. A comparison of alternative models for the demand for medical care. J Bus Econ Stat. 1983;1: 115-126.
33. Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247-281.
34. Pelletier KR. ROI research and worksite health promotion. Am J Health Promot. 1999;14:44-45.
35. Heckman JJ, Rob B. Alternative models for evaluating the impact of interventions: an overview. J Economet. 1985;30:239-267.
36. Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
37. Robins J, Mark S, Newey W. Estimating exposure effects by modeling the expectation of exposure conditional on confounders. Biometrics. 1992;48: 479-495.
38. Drake C, Fisher L. Prognostic models and the propensity score. Int. J Epidemiol. 1995;24:183-187.
39. Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. Prog Behav Modif. 1992;28:183-218.
40. Hoyle RH. Statistical Strategies for Small Sample Research. Thousand Oaks, CA: Sage Publications Inc; 1999.
41. O'Brien BJ, Drummond MF, LaBelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994;32:150-163.
42. O'Brien BJ, Drummond MF. Statistical versus quantitative significance in the socioeconomic evaluation of medicines. PharmacoEconomics 1994;5: 389-398.
43. Eddington ES. Randomization Tests. New York, NY: M Dekker; 1995.
44. Belsley DA, Kuh E, Welsch RE. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. New York, NY: John Wiley & Sons Inc; 1980.
45. Kmenta J. Elements of Econometrics. 2nd ed. New York, NY: Macmillan Publishing Company; 1986.
46. Gardiner J, Hogan A, Holmes-Rovner M, Rovner D, Griffith L, Kupersmith J. Confidence intervals for cost-effectiveness ratios. Med Decis Making. 1995;15:254-263.